The Italian Medicines Agency (Aifa) is preparing a pharmaceutical reform that could shift up to €1 billion in drug costs onto patients beginning in 2027, a move that has triggered a rare public dispute within the government and raised alarm among millions who depend on common medications for chronic conditions.
Why This Matters
• Your wallet: If you take statins, blood pressure medication, or acid reflux drugs, you may soon pay the difference if your doctor prescribes anything but the cheapest option in that therapeutic class.
• Timeline: The new National Pharmaceutical Formulary is scheduled to take effect January 1, 2027, though Health Minister Orazio Schillaci is pushing back and demanding more analysis.
• Budget backdrop: Italy's regional health systems blew through the pharmaceutical spending cap by €4.7 billion in 2025, triggering this cost-containment scramble.
The Mechanism: How Reference Pricing Would Expand
Currently, Italy's National Health Service (SSN) uses reference pricing only for drugs with the same active ingredient—generics and branded equivalents. The proposed revision would extend this mechanism to entire therapeutic categories, even when the medications contain different chemical compounds.
Under the new system, the SSN would reimburse only up to the price of the least expensive drug within a given treatment group. Choose a pricier alternative, and the difference comes out of your pocket. Aifa has already begun requesting price cuts from pharmaceutical companies, but most have declined.
The categories initially under scrutiny include some of the most-prescribed medications in Italy: statins for cholesterol management, sartans and ACE inhibitors for hypertension, proton pump inhibitors for gastric protection, and omega-3 supplements. These are daily medications for millions of Italians managing chronic conditions.
Political Clash Inside the Majority
Senator Annamaria Furlan, Italia Viva's health commission lead, accused the government of proceeding without a unified strategy. "The government gives the impression of moving forward without a shared line," she said, highlighting that Minister Schillaci expresses doubts and concerns about the operation, while Undersecretary Marcello Gemmato continues to support a different strategy on drug distribution, and Aifa President Robert Nisticò defends the agency's choices.
Schillaci has been explicit in his reservations, stating that citizens should not pay more for medicines and that access to innovative therapies must not be obstructed. The Ministry of Health has formally requested more robust technical, scientific, and economic analyses before proceeding, calling the current proposal more of a "methodological framework" than a fully supported plan.
Nisticò, meanwhile, maintains the revision is essential for system sustainability, arguing that updated evaluation tools are necessary as medicine becomes increasingly personalized.
What This Means for Patients
The practical impact hinges on prescribing patterns and pharmaceutical supply chains. If your cardiologist prescribes a newer or branded statin because it suits your specific clinical profile, you would face a co-payment for the difference between that drug and the generic reference price. Multiply that scenario across the therapeutic categories under review, and the cumulative burden approaches €1 billion annually across the patient population.
Patient advocacy groups and the pharmaceutical industry association Farmindustria have both raised concerns. The industry warns that aggressive pricing measures could discourage investment in the Italian market, exacerbate existing drug shortages, and reduce the availability of certain medications—a scenario already playing out in some European markets where strict cost controls have led manufacturers to withdraw or delay launches.
Furlan emphasized that cost containment cannot become a reduction in protections. "When we talk about drugs, we cannot dump the costs of system inefficiencies onto citizens," she said. "The first duty is not to compromise therapeutic continuity, prescriptive freedom of doctors, and the right of patients to receive the most appropriate treatments."
How Italy Compares to European Neighbors
Italy's approach contrasts with models in France and Germany, where out-of-pocket health spending by households is significantly lower—8.9% in France and 10.7% in Germany, compared to higher direct spending in Italy. These countries achieve better insulation of citizens through stronger public reimbursement coverage and centralized price negotiations with pharmaceutical companies.
Germany, for instance, reimburses 96% of oncology therapies, while Italy reimburses 80% of drugs approved by the European Medicines Agency—a relatively high figure, but paired with one of the lowest per-capita public pharmaceutical expenditures in Europe. Many northern European systems use Health Technology Assessment (HTA) to evaluate new drugs' clinical and economic value before setting reimbursement levels, a process that balances innovation access with budget discipline.
Managed Entry Agreements (MEAs), which Italy already employs for high-cost innovative drugs, tie reimbursement to real-world effectiveness. If a treatment doesn't deliver promised results, the pharmaceutical company refunds the cost. Expanding this model could offer a middle path between blanket cost-shifting and unchecked spending growth.
The Payback Problem and Regional Overspending
Italy's pharmaceutical budget operates under strict spending caps, with costs split evenly between regional governments and pharmaceutical companies when thresholds are breached. In 2025, regional purchases of drugs hit €4.7 billion, triggering payback obligations. This mechanism, intended to discipline spending, is not widely used in other major European countries, where flexible growth targets are preferred over rigid caps.
The tension illustrates a structural challenge: Italy's decentralized regional health systems have varying levels of efficiency and fiscal discipline, but the national government and Aifa bear ultimate responsibility for keeping aggregate spending within European Union fiscal constraints.
Other Healthcare Developments
Separately, a new contract for general practitioners working in Community Health Centers (Case di Comunità) was signed late Tuesday by regional representatives and the Fimmg and Fmt unions. Doctors will be required to work up to 6 hours weekly for 48 weeks annually in these centers, receiving €38.72 per hour in a nationally standardized compensation structure. The agreement must take effect by June 30, 2026, to comply with Italy's National Recovery and Resilience Plan (PNRR) deadlines.
Meanwhile, fresh data from Inps revealed that average retirement pensions for Italian women remain 34% lower than men's—€1,491.70 per month versus €2,260.60. The gap reflects persistent wage disparities: in 2024, average daily wages in the private sector were €111.10 for men and €82.60 for women, a difference of nearly 26%.
A Censis-Assogestioni report found that Italian workers expect their public pensions to replace only 48.4% of their final salary, yet fewer than one in five has joined a supplementary pension plan. Distrust, procrastination, and competing financial priorities keep participation low, even as workers say they would like to retire at 60 but expect to work until 69.
In a rare bright spot for labor relations, strike activity in Italy fell 5.5% in 2025 to 1,020 strikes, according to the national watchdog. However, general strikes doubled from 17 to 33, almost entirely driven by smaller grassroots unions.
What Happens Next
The pharmaceutical formulary debate is far from settled. Schillaci's request for deeper analysis suggests the Ministry of Health may slow or reshape Aifa's proposal before the scheduled 2027 rollout. Political pressure from opposition parties, patient groups, and industry lobbies is intensifying.
For residents managing chronic illness, the takeaway is to stay informed about your prescriptions and discuss alternatives with your physician now. If the reform proceeds as drafted, understanding which drugs fall under expanded reference pricing—and which therapeutic substitutions are clinically appropriate—will become a matter of household budgeting, not just medical advice.
